Literature DB >> 30597175

Monitoring healthcare-associated infections and antimicrobial use at regional level through repeated point prevalence surveys: what can be learnt?

L Arnoldo1, C Smaniotto2, D Celotto2, L Brunelli2, R Cocconi3, D Tignonsini3, A Faruzzo3, S Brusaferro4.   

Abstract

BACKGROUND: Healthcare-associated infections (HAIs) surveillance is an essential part of any infection prevention and control programme. Repeated point prevalence surveys (PPSs) according to European Centre for Disease Prevention and Control (ECDC) protocol have been implemented in all Friuli Venezia Giulia (FVG) region (Italy) acute hospitals to reduce and control HAIs. AIM: Using the repeated PPSs within a regional-healthcare system (RHS) to promote and evaluate infection prevention and control (IPC) programmes.
METHODS: The standard versions of the ECDC PPS protocols were used in all four surveys (2011, 2013, 2015, 2017). All RHS public and private accredited hospitals were involved within the 'safe care network' programme.
FINDINGS: The numbers of surveyed patients in the four PPSs were 3172, 3253, 2969 and 3036, respectively. Prevalence of HAIs and antimicrobial use (AU) decreased significantly from 2011: HAIs (P<0.05) 7.1%, 6.3%, 5.5%, 5.8% and AU (P<0.01) 40.4%, 39.2%, 36.0%, 37.2%, respectively. The appropriateness of duration of surgical prophylaxis increased significantly (<24 h increased through surveys related to one in 2011: odds ratio (OR), 95% confidence interval (CI) 1.29, 0.92-1.81; 1.95, 1.31-2.91; 1.78, 1.20-2.64, respectively). The most frequently detected HAIs were: bloodstream, urinary tract, pneumonia and surgical site (more than the 70% of HAIs in each PPS).
CONCLUSION: The FVG regional approach to HAIs and AU surveillance was able to contribute to reduce prevalence over a 7-year period. Furthermore, it was able to keep hospital attention on HAIs and AU through the years and to guarantee a standardized and comparable evaluation of HAIs and AU burden in all RHS hospitals, as well as impacting on HAIs and AU regional programmes.
Copyright © 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial use; Healthcare-associated infection; Infection prevention and control; Repeated prevalence

Mesh:

Substances:

Year:  2018        PMID: 30597175     DOI: 10.1016/j.jhin.2018.12.016

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

1.  Three-Year Trends of Healthcare-Associated Infections and Antibiotic Use in Acute Care Hospitals: Findings from 2016-2018 Point Prevalence Surveys in Sicily, Italy.

Authors:  Martina Barchitta; Andrea Maugeri; Maria Clara La Rosa; Claudia La Mastra; Giuseppe Murolo; Antonella Agodi
Journal:  Antibiotics (Basel)       Date:  2020-12-22

2.  Point prevalence survey is useful for introducing effective surveillance of healthcare-associated infections.

Authors:  Marjaana Pitkäpaasi; Jaana-Marija Lehtinen; Mari Kanerva
Journal:  Infect Prev Pract       Date:  2021-11-12

3.  Prevention of Surgical Site Infections in Neonates and Children: Non-Pharmacological Measures of Prevention.

Authors:  Aniello Meoli; Lorenzo Ciavola; Sofia Rahman; Marco Masetti; Tommaso Toschetti; Riccardo Morini; Giulia Dal Canto; Cinzia Auriti; Caterina Caminiti; Elio Castagnola; Giorgio Conti; Daniele Donà; Luisa Galli; Stefania La Grutta; Laura Lancella; Mario Lima; Andrea Lo Vecchio; Gloria Pelizzo; Nicola Petrosillo; Alessandro Simonini; Elisabetta Venturini; Fabio Caramelli; Gaetano Domenico Gargiulo; Enrico Sesenna; Rossella Sgarzani; Claudio Vicini; Mino Zucchelli; Fabio Mosca; Annamaria Staiano; Nicola Principi; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2022-06-27

4.  Analysis of Continuous Prevalence Survey of Healthcare-Associated Infections Based on the Real-Time Monitoring System in 2018 in Shandong in China.

Authors:  Jian Sun; Wen Qin; Lei Jia; Zhen Sun; Hua Xu; Yiyi Hui; Anman Gu; Weiguang Li
Journal:  Biomed Res Int       Date:  2021-06-11       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.